Role of Inhibitor of Yes-associated Protein 1 in Triple-negative Breast Cancer with Taxol-based Chemoresistance

Overview

Journal Cancer Sci

Specialty Oncology

Date 2018 Nov 24

PMID 30467925

Citations 22

Authors

Ying Li

Shunan Wang

Xi Wei

Sheng Zhang

Zian Song

Xiao Chen

Jin Zhang

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is highly clinically aggressive and taxol-based chemoresistance remains a big TNBC therapeutic problem to be solved. Verteporfin, a small molecular yes-associated protein 1 (YAP1) inhibitor, is little known as an antitumor drug for TNBC. Our data showed that YAP1 expression was associated with early relapse in tissue samples of patients with TNBC taxol chemoresistance (P < .001). Verteporfin reduced migration and enhanced apoptosis or autophagy of a taxol-resistant MDA-MB-231 cell line in vitro. Knockdown of YAP1 increased epithelial-mesenchymal transition response in a taxol-resistant TNBC cell line. In an in vivo experiment, we found that verteporfin was able to shrink tumor weight and volume and decreased Ki67 expression in a taxol-resistant mouse model. Our results provide evidence that verteporfin could be a chemosensitizer for TNBC patients with taxol-based treatment.

Citing Articles

METTL14 suppresses the expression of YAP1 and the stemness of triple-negative breast cancer.

Bai X, Liu J, Zhou S, Wu L, Feng X, Zhang P J Exp Clin Cancer Res. 2024; 43(1):307.

PMID: 39563370 PMC: 11577812. DOI: 10.1186/s13046-024-03225-2.

Rab3B Proteins: Cellular Functions, Regulatory Mechanisms, and Potential as a Cancer Therapy Target.

Xu J, Zhang H, Yang L Cell Biochem Biophys. 2024; 83(1):263-277.

PMID: 39320613 DOI: 10.1007/s12013-024-01549-6.

Unleashing the Power of Yes-Associated Protein in Ferroptosis and Drug Resistance in Breast Cancer, with a Special Focus on Therapeutic Strategies.

Malla R, Kundrapu D, Bhamidipati P, Nagaraju G, Muniraj N Cancers (Basel). 2023; 15(24).

PMID: 38136274 PMC: 10741587. DOI: 10.3390/cancers15245728.

Hypoxia-induced YAP activation and focal adhesion turnover to promote cell migration in mesenchymal TNBC cells.

Nguyen T, Lai Y, Chen Y, Lin T, Nguyen N, Chiu W Cancer Med. 2023; 12(8):9723-9737.

PMID: 36757143 PMC: 10166962. DOI: 10.1002/cam4.5680.

Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective.

Pal A, Sharma P, Zia A, Siwan D, Nandave D, Nandave M Pathophysiology. 2022; 29(2):200-222.

PMID: 35736645 PMC: 9230911. DOI: 10.3390/pathophysiology29020017.

References

Huggett M, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M . Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014; 110(7):1698-704. PMC: 3974098. DOI: 10.1038/bjc.2014.95. View

Liu A, Xu Z, Luk J . An update on targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther Targets. 2012; 16(3):243-7. DOI: 10.1517/14728222.2012.662958. View

Xu M, Yao T, Lee N, Ng I, Chan Y, Zender L . Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009; 115(19):4576-85. PMC: 2811690. DOI: 10.1002/cncr.24495. View

Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M . YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis. 2010; 32(3):389-98. DOI: 10.1093/carcin/bgq254. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Avruch J, Zhou D, Bardeesy N . YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle. 2012; 11(6):1090-6. PMC: 3335916. DOI: 10.4161/cc.11.6.19453. View

Li Y, Wang S, Wei X, Zhang S, Song Z, Chen X . Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance. Cancer Sci. 2018; 110(2):561-567. PMC: 6361558. DOI: 10.1111/cas.13888. View

Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U . Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006; 8(4):R34. PMC: 1779468. DOI: 10.1186/bcr1517. View

Tschaharganeh D, Chen X, Latzko P, Malz M, Gaida M, Felix K . Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013; 144(7):1530-1542.e12. PMC: 3665638. DOI: 10.1053/j.gastro.2013.02.009. View

10.

Pantalacci S, Tapon N, Leopold P . The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol. 2003; 5(10):921-7. DOI: 10.1038/ncb1051. View

11.

Gurda G, Zhu Q, Bai H, Pan D, Schwarz K, Anders R . The use of Yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease. Hum Pathol. 2014; 45(5):1057-64. PMC: 4151519. DOI: 10.1016/j.humpath.2014.01.002. View

12.

Wang K, Degerny C, Xu M, Yang X . YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol. 2009; 87(1):77-91. DOI: 10.1139/O08-114. View

13.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

14.

Zhao B, Li L, Lei Q, Guan K . The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010; 24(9):862-74. PMC: 2861185. DOI: 10.1101/gad.1909210. View

15.

Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F . BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006; 5(9):1001-7. DOI: 10.4161/cc.5.9.2726. View

16.

Eckstein N, Haas B . [Platinum-based chemotherapy in triple negative breast cancer]. Dtsch Med Wochenschr. 2012; 137(7):333-6. DOI: 10.1055/s-0031-1298891. View

17.

Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller J . The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 2014; 124:67-73. PMC: 4135181. DOI: 10.1016/j.exer.2014.04.011. View

18.

Zhang X, George J, Deb S, Degoutin J, Takano E, Fox S . The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011; 30(25):2810-22. DOI: 10.1038/onc.2011.8. View

19.

Huang J, Wu S, Barrera J, Matthews K, Pan D . The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005; 122(3):421-34. DOI: 10.1016/j.cell.2005.06.007. View